Seize the engine: Emerging cell cycle targets in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer involves cell cycle disruptions, leading to uncontrolled proliferation and genomic instability.
• Targeting cell cycle regulators is a key anti-cancer strategy, but early attempts faced challenges with selectivity and toxicity.
• Recent advances illuminate resistance mechanisms to CDK4/6 inhibitors, renewing focus on novel cell cycle targets.

Purpose of the Study:

• To review emerging cell cycle targets beyond CDK4/6 for breast cancer treatment.
• To discuss the biological roles and drug development potential of these novel targets.
• To highlight inhibitors with promising safety and efficacy in clinical trials.

Main Methods:

• Literature review of preclinical and clinical studies on novel cell cycle targets.
• Analysis of the molecular mechanisms underlying cell cycle regulation in breast cancer.
• Evaluation of drug development strategies and clinical trial data for emerging inhibitors.

Main Results:

• Several novel cell cycle targets (e.g., CDK2, CDK7, WEE1, AURKA) show potential in preclinical models.
• These targets may overcome resistance to CDK4/6 inhibitors and sensitize tumors to immunotherapy.
• Many novel inhibitors demonstrate favorable safety profiles and promising clinical activity.

Conclusions:

• Emerging cell cycle targets represent a promising avenue for overcoming resistance in breast cancer therapy.
• Targeting specific cell cycle components offers potential for improved efficacy and reduced toxicity.
• Further clinical investigation of these novel inhibitors is warranted.